Copernicus Capital Management, LLC
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Sep 30, 2021, never from the firm's own description.
Closest benchmark: the Dow Jones Industrial Average as of 2021-10-31, active share 97.0%; sector active share 82.9% against the combined 13F book's sector weights.
Over time 7 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
13 tracked positions · as of Sep 30, 2021 · Δ vs Jun 30, 2021Portfolio Trend
Sector Breakdown
As of Sep 30, 2021| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 92.0% | $7,604,700 |
| Unclassified | 8.0% | $657,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics Inc | +2,000 | 12,000 | $711,240 | |
| — | +1,000 | 6,000 | $657,000 | ||
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RCUS | Arcus Biosciences, Inc. | −3,000 | 17,000 | $592,790 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| PFE | Pfizer Inc | 30,000 | $1,290,300 | |
| TMO | Thermo Fisher Scientific Inc. | 2,000 | $1,142,660 | |
| TDOC | Teladoc Health, Inc. | 7,000 | $887,670 | |
| BMRN | Biomarin Pharmaceutical Inc | 11,000 | $850,190 | |
| JNJ | Johnson & Johnson | 5,000 | $807,500 | |
| ALLO | Allogene Therapeutics, Inc. | 15,000 | $385,500 | |
| MDT | Medtronic plc | 3,000 | $376,050 | |
| PRQR | ProQR Therapeutics N.V. | 40,000 | $334,800 | |
| IMTX | Immatics N.V. | 10,000 | $130,000 | |
| — | 10,000 | $96,000 | ||
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | 9,000 | $1,814,670 | |
| ATRA | Atara Biotherapeutics, Inc. | 50,000 | $777,500 | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 10,000 | $532,000 | |
| — | 30,000 | $492,000 | ||
| — | 7,000 | $380,000 | ||
| JAZZ | Jazz Pharmaceuticals plc | 2,000 | $355,280 | |
| — | 35,000 | $320,000 | ||
| SKIN | SkinHealth Systems Inc. | 10,000 | $168,000 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PFE |
Pfizer Inc
Healthcare
|
NEW | 30,000 | $1,290,300 | 15.62% | |
| TMO |
Thermo Fisher Scientific Inc.
Healthcare
|
NEW | 2,000 | $1,142,660 | 13.83% | |
| TDOC |
Teladoc Health, Inc.
Healthcare
|
NEW | 7,000 | $887,670 | 10.74% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
NEW | 11,000 | $850,190 | 10.29% | |
| JNJ |
Johnson & Johnson
Healthcare
|
NEW | 5,000 | $807,500 | 9.77% | |
| FATE |
Fate Therapeutics Inc
Healthcare
|
Added | 12,000 | $711,240 | 8.61% | |
|
|
Added | 6,000 | $657,000 | 7.95% | ||
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
Reduced | 17,000 | $592,790 | 7.18% | |
| ALLO |
Allogene Therapeutics, Inc.
Healthcare
|
NEW | 15,000 | $385,500 | 4.67% | |
| MDT |
Medtronic plc
Healthcare
|
NEW | 3,000 | $376,050 | 4.55% | |
| PRQR |
ProQR Therapeutics N.V.
Healthcare
|
NEW | 40,000 | $334,800 | 4.05% | |
| IMTX |
Immatics N.V.
Healthcare
|
NEW | 10,000 | $130,000 | 1.57% | |
|
|
NEW | 10,000 | $96,000 | 1.16% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.